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ABSTRACT 
Aims of the study: To assess the prevalence of Antiepileptic Drug (AED) exposure in 
pregnant women with or without epilepsy and the comparative risk of  terminations of 
pregnancy (TOPs), spontaneous abortions, stillbirth, major congenital malformations (MCMs) 
and foetal growth retardation (FGR) following intrauterine AED exposure in the Emilia 
Romagna region (RER), Northern Italy (4 million inhabitants).  
Methods: Data were obtained from official regional registries: Certificate of Delivery 
Assistance, Hospital Discharge Card, reimbursed prescription databases and Registry of 
Congenital Malformations. We identified all the deliveries, hospitalized abortions and MCMs 
occurred between January 2009 and December 2011.  
Results: We identified 145,243 pregnancies: 111,284 deliveries (112,845 live births and 279 
stillbirths), 16408 spontaneous abortions and  17551  TOPs. Six hundred and eleven 
pregnancies (0.42% 95% Cl: 0.39-0.46) were exposed to AEDs.  Twenty-one per cent of 
pregnancies ended in TOP in the AED group vs 12% in the non-exposed (OR:2.24; CI 1.41-
3.56). The rate of spontaneous abortions and stillbirth was comparable in the two groups. 
Three hundred fifty-three babies (0.31%, 95% CI: 0.28-0.35) were exposed to AEDs during 
the first trimester. The rate of MCMs was 2.3% in the AED group (2.2% in babies exposed to 
monotherapy and 3.1% in babies exposed to polytherapy) vs 2.0% in the non-exposed. The 
risk of FGR was 12.7 % in the exposed group compared to 10% in the non-exposed. 
Discussion and Conclusion: The prevalence of AED exposure in pregnancy in the RER was 
0.42%. The rate of MCMs in children exposed to AEDs in utero was almost superimposable 
to the one of the non-exposed, however polytherapy carried a slightly increased risk . The 
rate of TOPs was significantly higher in the exposed women. Further studies are needed to 
clarify whether this high rate reflects a higher rate of MCMs detected prenatally or other 
more elusive reasons. 
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1. BACKGROUND 
Epilepsy is a chronic condition affecting 0.3-0.8% of pregnant women in developed countries 
(Olafsson et al., 1998; Richmond et al., 2004; Viinikainen et al., 2006;  Borthen et al., 2011). 
Most patients require long-term therapy with antiepileptic drugs (AEDs) that cannot be 
suspended during pregnancy due to the potentially adverse effects of seizures on women 
and their offspring.  Seizures, especially if tonic-clonic, can lead to severe injury and even 
death. A recent report of the United Kingdom Confidential Enquiries into Maternal Deaths 
showed that, in the triennium 2006-2008, 5.4% of the deaths during pregnancy or 
puerperium were epilepsy-related (CMACE 2011; Edey et al, Epilepsia 2014). Moreover, 
several reports raise concern about a possible detrimental effect of maternal generalized 
tonic-clonic seizures (GTCS) on the foetus. Teramo et al. described two cases in which 
foetal heart rate was recorded during a maternal epileptic seizure during labour, showing in 
both a pattern of bradycardia followed by decreased short-term and long-term variability, with 
clear fetal asphyxia in the most severe case. It was postulated that the increase in 
intrauterine pressure during a seizure might decrease the uteroplacental blood flow.  
(Teramo et al., 1979). A case of fetal intracranial hemorrhage after a maternal seizure was 
also reported (Minkoff H et al., 1985). Traumatic foetal injury after maternal seizures and 
foetal loss after a GTCS-status were also described (EURAP Study Group, 2006).  
Women without epilepsy may also be exposed to antiepileptic drugs (AEDs) during 
pregnancy, as these drugs are increasingly used for other diseases, among which bipolar 
mood disorder, migraine and neuropathic pain (See Appendix 2. AEDs indications other than 
epilepsy). Besides, most women with bipolar disorder should not even discontinue therapy 
during pregnancy, as this can raise the risk of relapse of more than twofold (Viguera et al., 
2007).  
Accordingly, the prevalence of AED use in pregnant women is 0.2% to 2.2% and it shows an 
increasing trend in some studies (Czeizel et al., 1992; Malm et al., 2003; Wide et al., 2004; 
Bobo et al., 2012; Kilic et al., 2014; Wen et al., 2015).  
Exposure to older generation AEDs, such as phenobarbital (PB), phenytoin (PHT), valproate 
(VPA) and carbamazepine (CBZ), during the first trimester of pregnancy, the period of 
organogenesis, has been consistently associated with an approximately 2- to 3-fold 
increased risk of major congenital malformations (MCMs): 4-10% vs 2-5% in the general 
population (Perucca, 2005). Malformation rates associated with a specific AED vary 
considerably between studies, depending on population and methodological approaches.  
However, VPA, compared to other AEDs, was almost invariably associated with a higher 
incidence of MCMs, varying between 4.7% and 54.5%, in a dose-dependent manner (Wide 
et al., 2004; Perucca, 2005; Vajda et al., 2005; Wyszynski et al., 2005; Morrow et al., 2006; 
Meador et al., 2008; Cunnington et al., 2011; Holmes et al., 2011; Tomson et el.,  2011; 
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Campbell et al., 2014; Vajda et al., 2014). In particular, VPA use has been associated with 
spina bifida, hypospadia, atrial septal defect, polydactily, cleft palate and craniosynostosis 
(Jentik et al., 2010a). 
PHT was the first AED in which teratogenicity was noted and a specific “fetal hydantoine 
syndrome”, including facial dysmorphism, mental retardation and delayed intrauterine growth 
was recognized (Loughnan et al., 1973, Hanson et al., 1975); subsequent studies reported 
variable incidence (0.7-9.1%) of MCMs in women exposed to PHT (Canger et al., 
1999;Perucca 2005;  Hernandez-Diaz et al., 2012), which however is currently little used in 
women of childbearing age.  
Early studies did not consider PB as a highly teratogenic medication, although a relative 
specific risk of cardiac defects and facial clefts was reported (Samren et al. ,1999), whereas 
newer studies found an increased risk of MCMs overall, with an incidence ranging from 4.9% 
to 7.4 % (Holmes et al., 2001; Holmes et al., 2004; Meador, et al. 2008; Tomson et al., 2011; 
Hernandez-Diaz et al., 2012; Tomson and Battino 2012).  
CBZ has been associated with spina bifida with a 5-fold higher risk than the general 
population, as well as orofacial clefts, hypospadia and heart defects; however it is 
considered less teratogenic than the other older AEDs, with an overall incidence of MCMs 
comprised between 1.9 and 7.3% in various studies (Rosa et al., 1991; Jentink et al., 2010b; 
Tomson et al., 2011; Hernandez-Diaz et al., 2012; Campbell et al., 2014). 
Since the 1990s, several newer AEDs have been licensed; their use has been constantly 
increasing and, being considered safer, some of them, and namely lamotrigine (LTG) and 
levetiracetam (LEV), are currently the most used AEDs in women of childbearing age 
(Meador et al., 2009) and during pregnancy in developed countries (Moolgard-Nielsen and 
Hviid, 2011; Wen et al., 2015). 
LTG has been associated with craniofacial defects, particularly cleft palate, in some studies 
(Vajda et al., 2005; Morrow et al., 2006; Holmes et al., 2008a) but not in others (Dolk et al., 
2008; Cunnington et al., 2011). The overall risk of MCMs with LTG in monotherapy varies 
between 1.8 and 5.4 % and it is dose-dependent (Cunnington et al., 2011; Tomson et al., 
2011; Hernandez-Diaz et al., 2012; Campbell et al.,2014).  
Data have been accumulating on levetiracetam and, so far, there is no evidence of 
teratogenicity for this drug in monotherapy (Artama et al., 2005; Montouris et al., 2005; 
Morrow et al., 2006; Hunt et al., 2006 ;  Holmes et al., 2008; Molgaard-Nielsen and Hviid, 
2011; Tomson et la., 2011; Mawhinney et al., 2013; Chauhdry et al., 2014; Vajida et al. 
2014). 
Recent studies reported an increased risk of MCMs after topiramate (TPM) exposure  during 
pregnancy, ranging from 2.4% to 6.9%, and in particular of cleft palate, which showed an 
incidence of more than 10 times the background, and hypospadia. TPM teratogenicity seems 
to be enhanced in polytherapy with other AEDs  (Hunt et al., 2008; Moolgard-Nielsen and 
Hviid, 2011; Tomson et al., 2011; Hernandez-Diaz et al., 2012; Margulis et al., 2012; Mines 
et al., 2014). 
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Oxcarbazepine and gabapentin have not been associated with a significant higher risk of  
MCMs in monotherapy but caution is needed in interpreting published data, due to the low 
number of women exposed in monotherapy (Montouris et al., 2005; Morrow et al., 2006; 
Molgaard-Nielsen and Hviid, 2011; Tomson et al., 2011; Hernandez-Diaz et al., 2012; Fuji et 
al., 2013;   Guttuso et al., 2014; Veiby et al., 2014).  
Published data on the teratogenicity of vigabatrin, felbamate, zonisamide, pregabalin, 
rufinamide, lacosamide, retigabine and tiagabine are scanty or absent.  
The risk of MCMs appears to increase with polytherapy, especially if containing VPA 
(Morrow et al., 2006). Indeed, recent studies showed an increased risk rate of LTG and CBZ 
in polytherapy compared to monotherapy only when VPA was included  (Cunnington et al., 
2011; Holmes et al., 2011).  
Rates of MCMs increase with increasing dosages of the drugs and this is particularly the 
case with VPA (Morrow et al., 2006; Tomson et al, 2011; Hernandez-Diaz S et al., 2012; 
Campbell et al.,2014). It has been suggested that incidence of MCMs associated with a low 
dose of a higher-risk drug might be comparable to that associated with a high dose of a 
lower-risk drug, which may have a major clinical impact when seizures are not controlled by 
one of the latter. (Morrow et al.2006; Tomson et al., 2011). 
Although some studies found an increased prevalence of MCMs in children born to untreated 
women with epilepsy (WWE) (Morrow et al., 2006) a comprehensive review of the literature 
and more recent studies do not support the hypotheses of an association between epilepsy 
per se and a major increase in the risk of MCMs (Holmes et al., 2001; Fried S et al., 2004). 
In addition, a recent large study did not find an association between epilepsy type or 
generalized tonic-clonic seizures in the first trimester and MCMs risk (Tomson et al., 2011).   
Parental history of MCMs was related to a 4-fold higher risk (Tomson et al., 2011). In one 
study, the risk of having a child with an MCM was higher in women who have had another 
child with an MCM while on AEDs (Campbell et al., 2013). This was not confirmed in another 
study (Begum et al., 2013). 
Folate intake during preconception and first trimester of pregnancy might reduce the risk of 
neural tube, cardiovascular and urinary tract defects and oral clefts in infants born to healthy 
women (MRC Vitamin Study Research Group, 1991; Berry et al.,1999) and folates at the 
dose of 400 mcg per day are recommended in all women planning a pregnancy. For women 
using AEDs which are disruptors of folate metabolism (i.e., PB, CBZ, PHT, primidone, and, 
to a lesser extent, LTG) or carry an increased risk for spina bifida (i.e. VPA, CBZ), the 
routinely recommended dose could be insufficient and it has been suggested that a dose of 
at least 4 mg per day should be prescribed (Wilson et al., 2003). However, whether folate 
intake reduces the risk of MCMs in infants born to women taking AEDs remains unclear and 
several studies failed to find any protective effect (Yerby et al., 2003; Tomson et al., 2011).   
Until recent times studies on AEDs use in pregnancy have focused mainly on the risk of 
MCMs, and less is known on other possible adverse foetal outcomes. 
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A systematic review found no evidence of an increased risk of spontaneous abortion in 
WWE (Harden et al., 2009) and this was confirmed in a recent population-based study (Bech 
et al., 2014).  
Data on stillbirths in WWE are conflicting:  it was reported both that their incidence was 
comparable to that of the general population (Olafsson et al., 1998) and that they were up to 
twice as common (Waters et al. 1994, Richmond et al., 2004).  
In a recent population study preterm deliveries were more common in women using AEDs, 
but only for indications other than epilepsy (Killic et al., 2014). 
A systematic review of the literature and several subsequent studies showed that fetal 
growth retardation and the risk of being small for gestational age are more common in 
women taking AEDs (Hvas et al., 2000; Artama et al., 2013;Killic et al.; 2014 Veiby et al. 
2014), while a cohort study claimed that the risk could be increased on polytherapy but not 
on monotherapy (Wide et al., 2000) and other studies did not report an increased frequency 
(Lin et al., 2009; Mawer et al., 2010). 
A recent retrospective Brazilian study showed a greater incidence of mortality and  
hemorrhagic disorder  in newborns exposed to AEDs in utero. However 70% of the babies 
were exposed to PB which, being an enzyme-inducer, interferes with the metabolism of 
vitamin K (Barroso et al., 2014). In Italy all newborns routinely receive vitamin K at delivery, 
and at present no further measures are advised in neonates exposed to AEDs (Harden et 
al., 2009).  
The number of cesarean sections among WWE did not differ from the controls in a study, 
while it was increased up to 2-fold in others (Olafsson et al., 1998; Borthen et al., 2010; 
Borthen et al., 2011). 
Little is known on the relevance of the clinical indication for AEDs to the fetal outcome. In 
addition to the observations on untreated WWE and to the mentioned study by Killic et al., it 
is worth mentioning a recent Swedish population based study, showing that bipolar mood 
disorder per se, irrespective of therapy,  increases the risk of planned cesarean delivery, 
preterm birth, microcephalia, small for gestational age infants, neonatal hypoglicemia (Boden 
et al., 2012). 
 
Until the 1990s, data on AEDs teratogenicity were sparse and relied mainly on 
underpowered observational studies. In fact, due to the low risk of specific MCMs, 
observational studies require very large numbers of patients to obtain reliable data. Currently 
the main sources of data on AEDs safety in pregnancy are pregnancy registries, some 
conducted by the pharmaceutical industry, some by independent healthcare professionals. 
Although registry-based studies considerably increased the information on the topic, they 
have several limitations. Many of them enrol only WWE, excluding women taking AEDs for 
other disorders and most studies have voluntary enrolment which may introduce selection 
biases towards high risk or low risk populations. Some studies include only patients from 
epilepsy centres, who could have more severe forms of epilepsy and thus a more aggressive 
treatment regimen. This may introduce a bias towards higher risk or, on the contrary, a more 
rational treatment regimen could introduce a bias towards lower risk. Some registries 
exclude women who already have some knowledge of foetal status, including possible 
MCMs, having undergone ultrasound at 16-20 weeks of gestation, thus possibly 
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underestimating MCMs rates. Data collection from many different investigators is difficult to 
standardize in large multicentric studies. Some registries have a considerable loss to follow-
up rate, and most lack of information on adverse outcomes other than major MCMs, 
including pregnancy losses and stillbirth. Finally, many studies lack of comparison with an 
unexposed population. 
A large population-based study can address many of these limits yielding information on 
pregnancy outcomes in the whole population of pregnant women, exposed and unexposed 
to AEDs. 
The Emilia Romagna Region (RER) collects data on deliveries, abortions, MCMs and drug 
prescriptions in official registries: Certificate of Delivery Assistance registry (CedAP); 
Hospital Discharge Card (SDO) registry (ICD codes related to pregnancy and abortion); 
databases of all the reimbursed prescriptions in RER: AFT (prescriptions supplied by private 
pharmacies), DD (prescriptions supplied by hospital pharmacies to outpatients) and DPC 
(prescriptions supplied by private pharmacies on behalf of hospital pharmacies) and  the 
Emilia Romagna birth defects register (IMER). Data from the different registries are available 
and can be linked.   
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AIMS 
 
Primary aims of the study were: 
1) to assess the prevalence of AEDs exposure during pregnancy (any stage) in women with 
and without epilepsy in the RER; 
2) to describe the AEDs prescription patterns in pregnant women with and without epilepsy; 
3) to determine the incidence and comparative risk of MCMs following AEDs monotherapy or 
polytherapy during the first trimester of pregnancy. 
 
Secondary aims were: 
1) to determine the incidence and comparative risk of MCMs following the intake of any 
specific AED during the first trimester of pregnancy; 
2) to determine the incidence and comparative risk of specific MCMs following AEDs 
monotherapy or polytherapy during the first trimester of pregnancy; 
3) to determine the incidence and comparative risk of MCMs overall and the specific risk of 
MCMs in infants born to WWE exposed to any AED on monotherapy and polytherapy during 
the first trimester of pregnancy; 
4) to determine the incidence and comparative risk of foetal growth retardation (FGR), 
stillbirth, spontaneous and induced abortions in women exposed to AEDs during pregnancy; 
5) to create a permanent surveillance system of pregnancy outcomes in women taking AEDs 
in the RER. 
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3. METHODS 
 
3.1 Local ethical committee approval   
The study started after approval of the Local Ethical Committee, obtained on 21/2/2013 and 
Hospital Health Direction (Direzione Sanitaria) authorization (determination 464, 13/3/2013). 
 
3.2 Preliminary study: identification of AEDs prescription patterns in women with and 
without epilepsy 
This step of the study was designed to identify prescription patterns allowing us to 
discriminate women using AEDs according to the clinical indication: epilepsy or other 
diseases. Most indications are very unlikely in pregnancy either because very rare in young 
women (i.e. essential tremor) or because they allow a withdrawal in pregnancy (i.e. 
prophylaxis of migraine).  Therefore we considered, as alternative to epilepsy, only 
psychiatric disturbances, conditions in which the therapy is generally maintained.   
3.2.1 Population: Women referring to the Bologna Health Trust  (380.181 inhabitants in 
2010), aged 18 - 45 years who for a six-month period comprised between the 1st of January 
and the 30th of June 2010 or 2011: 
– had an established diagnosis of epilepsy and underwent at least one visit at the Epilepsy 
Centre of the ISNB of Bologna  (Epilepsy cohort: EPI)  
Or 
-had an established diagnosis of psychiatric disorder, and underwent at least one visit at the 
Mental Health Department, Bologna Health Trust; women with a concomitant diagnosis of 
epilepsy were excluded (Psychiatric disorders cohort: PSY) 
And  
- had at least two prescriptions of AEDs (ATC - the Anatomical Therapeutic Chemical 
Classification system- code: N03A) (www.whocc.no) during the first semester of 2010 
or 2011. 
 
3.2.2 Recruitment   
A maximum number of 100 clinical charts for each cohort were consecutively selected  from 
the archives of the Epilepsy Centre of the ISNB of Bologna and of the Mental Health 
Department, Bologna Health Trust. Charts were manually screened, starting from those 
recorded for the first time in 2011 and going backward in time, until the final number was 
reached or until screening of the whole archive. 
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3.2.3 Prescription data sources 
Data on the reimbursed prescriptions of the selected women were obtained from two 
pharmaceutical regional databases: Sistema Informativo Territoriale (SIT) and Assistenza 
Farmaceutica Territoriale (AFT).  
3.2.4 Collection of data 
The following data were collected:  
Active substance:  Substances classified as AEDs (ATC code N03A), antipsychotics (ATC 
code  N05A), lithium (ATC code N05AN01) and antidepressants (ATC code N06A) were 
considered. 
Average daily dose: It was calculated as the ratio between the total dose and the observation 
period 
Intensity of treatment: It was expressed as the ratio between the average daily dose and the 
Daily Defined Dose (DDD). The DDD is a standardized unit of measure, established by the 
World Health Organization (WHO),  defined as the assumed average maintenance dose per 
day for a drug used for its main indication in adults in monotherapy. It is commonly used in 
pharmaco-utilization studies as it allows comparisons among different populations and 
periods of observation.  
3.2.5 Statistical analysis 
Creation of a classification tree: We used a hierarchical classification model to group 
women according to the type of disorder: epilepsy or psychiatric disorder. The goal was to 
predict which women can be successfully allocate to the disorder group on the basis of the 
following clinical information:  number of AEDs, number of antidepressants, number of 
antipsychotics, 42 single active substances belonging to those classes, intensity of treatment 
. The classification model was built using the rpart  package (version 4.1-8)  in R version 
3.0.3. This approach selects a hierarchical sequence of partitions in which the split that 
maximizes the improvement of predictive power is chosen at every step. In order to avoid an 
over fitting of the data we selected a tree size after inspection of the relative error of each 
size.  
The classification tree was estimated using data (training data set) of the two cohorts of 
women. We measured the performance of the model in the training dataset by the  error 
rate: percentage of women incorrectly classified.  
Validation of the classification tree:  We tested the classification tree using external data 
(test data set),which have not contributed to the construction of the algorithm itself, and 
namely prescription data of 50 women, aged 18-45 years, who received a prescription of 
AEDs, but resident in a different area of the RER, the Ferrara Local Health Authority (358116 
inhabitants in 2013).  We  used a three-step method:  
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First step:  The Ferrara Health Trust supplied the prescription data concerning AEDs, 
antipsychotics and antidepressants, without disclosing whether the women belonged to the 
EPI or PSY cohort; 
Second step:  The hierarchical classification estimated using the training population was 
applied to the test population;  
Third step : The cohorts were disclosed and the performance of the classification tree 
verified 
 
3.3 Main study  
3.3.1 Design 
Retrospective observational population-based study. 
3.3.2 Data sources and period of observation 
Data were obtained from the following official regional registers:  
Certificate of Delivery assistance (Certificato di  Assistenza al Parto - CedAP): the certificate 
of delivery assistance registry was instituted in 2002 and records all deliveries in the regional 
territory including stillbirths and home childbirths. It is a nationwide registry. The following 
data are recorded: birth site, personal and socioeconomic information on parents, maternal 
obstetric history, pregnancy course, labour and delivery, neonate, malformations, stillbirths 
(http://salute.regione.emilia-romagna.it/siseps/sanita/cedap/files/Cedap_Rapporto_Nascita_2012.pdf); 
Hospital Discharge Card (SDO): it contains the ICD codes of the discharge diagnosis; 
Reimbursed drug prescription registries: SIT (Sistema Informativo Territoriale ),  AFT 
(Assistenza Farmaceutica Territoriale), DD (Distribuzione Diretta) and DPC (Distribuzione 
Per Conto) include all reimbursed prescriptions supplied to RER inhabitants. In particular, 
AFT records data from private pharmacies, while DD and DPC record drugs supplied by 
hospital pharmacies to outpatients. Each registry provides the following information: 
prescription date, unique code of drugs (that allows linkage with ATC and DDD archives), 
number of packages and units; 
Emilia Romagna Registry of Congenital Malformations (IMER): the congenital malformation 
registry of the RER was instituted in 1978 in a few hospitals in the RER and since 1983 it 
has been a population-based program: yearly 40,000 births (coverage >95% of all births).  
Stillbirths at 26 weeks or more are included. Terminations of pregnancy have been collected 
since 1992. Reporting is made by a neonatologist and pediatricians during the first week of 
the infant’s life. Selected malformations are followed up. Detailed exposure information is 
obtained by interviews of the mother of malformed infants (www.registroimer.it) 
CedAP, SDO and drug prescription registries can be linked by a unique anonymous patient 
code. 
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IMER was linked to CEDAP using the following information: place of birth, child’s date of 
birth, maternal date of birth, maternal residence. In case of multiple CeDAP cases linking to 
a single IMER case, the linkage was further refined using the following information: paternal 
date of birth, last menstruation period.  
The period of observation was January 2009- December 2011. 
 
3.3.3 Identification of  pregnancies (deliveries and abortions)   
We identified women inhabitants of RER who had had a delivery from the CEDAP and 
women inhabitants of RER who had had an abortion (induced or provoked) from the SDO 
(ICD codes related to abortions).  
 
3.3.4 Drug exposure description  
Active substances: The following AEDs (active substances) registered in Italy were 
considered: Phenobarbital (PB), Primidone (PRI), Phenytoin (PHT), Ethosuximide (ETS), 
Clonazepam (CNZ), Carbamazepine (CBZ), Oxcarbazepine (OXC), Rufinamide (RFN), 
Valproic acid (VPA), Vigabatrin (VGB), Tiagabine (TGB), Lamotrigine (LTG), Felbamate 
(FBM), Topiramate (TPM), Gabapentin (GBP), Levetiracetam (LEV), Zonisamide (ZNS), 
Pregabalin (PGB), Lacosamide (LCM). 
Periods of observation: 
Deliveries cohort: On the basis of the date of delivery and the gestational age at that time, 3 
time periods were identified for each woman: the year preceding the delivery, the pregnancy 
period and the first trimester. For each period, exposure to AEDs was identified on the basis 
of prescriptions received, obtained by AFT, DD and DPC;  
Abortions cohort: As the gestational age at the time of abortion is not traceable, we 
established to fix the trimester preceding the event as the AEDs exposure period in 
pregnancy; 
Average daily dose: It was calculated as the ratio between the total amount of drug 
prescribed in the observation period and the number of days.   
Stratification according to clinical indication 
The exposed women were assigned to the EPI or the PSY group, according to the clinical 
indication drawn by the algorithm developed in the preliminary study. For this purpose we 
considered the prescribing data of the first six months of observation. 
 
3.3.5 Identification and analysis of MCMs  
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Expert neonatologists reviewed every neonatal and foetal case detected through the IMER 
and separated cases of isolated MCM from cases with multiple congenital anomalies. 
Syndromic cases were included. Malformations were coded using a BPA (British Paediatric 
Association) modification of the WHOs ICD-9 (International Classification of Diseases, 
version 9) system (BPA, 1979).  
 
3.3.6 Identification of stillbirths and foetal growth retardation  
Stillbirths and cases of foetal growth retardation (FGR) were drawn from the CEDAP. FGR 
was defined as birthweight below the 10th percentile of the gender-specific birthweight for 
gestational age reference curves (WHO 1995). 
 
3.3.7 Confounding factors 
Maternal age, maternal education and smoking habit were drawn from the CEDAP. 
Reimbursable prescribed drugs belonging to FDA pregnancy categories X (contraindicated 
in pregnancy) or D (positive evidence of risk) were drawn from drug prescription registries. 
Maternal and foetal diseases that could affect the outcome were drawn from the SDO 
registry and drugs that could be considered proxy of maternal disease (ie: Insulin for 
diabetes) were drawn from the prescription registries.  
 
3.3.8  Statistical analysis  
We estimated the rough Odds Ratios  for abortion and MCM for AED exposure, using the 
variable as dichotomic and categorical (no AED, one AED, more AEDs). We also adjusted 
the Odds Ratios for MCMs  for maternal confounding factors (age, education, smoking habit, 
diabetes, prescription of drugs belonging to X and D FDA pregnancy categories) and foetal 
confounding pathologies of different etiologies (i.e.  cromosomopathy, infections, suspected 
radiation damage). 
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4. RESULTS 
 
4.1 Identification of AEDs prescription patterns in women with and without epilepsy 
Eighty-one subjects with epilepsy (EPI) and 94 with psychiatric diseases (PSY) were 
enrolled.  
 
Figure 1- Flow chart of enrolled patients 
100 patients recruited from the Mental Health Department and  
95 patients recruited from the Epilepsy Centre  
  
                                                                                                14 EPI pts and 6 PSY  pts with a single   prescription in the  
                                                                                               period of   observation                                                                                       
 
                                                                                                     
                                
                                     81 EPI pts and 94 PSY pts confirmed eligible and enrolled                 
                     
 
AED monotherapy was the most common choice in both groups (69% EPI vs 79% PSY, 
p=0.15).   
Phenobarbital, levetiracetam and zonisamide were used only in EPI, while pregabalin and 
gabapentin exclusively in PSY. 
The intensity of treatment was higher in EPI than in PSY for clonazepam (0. 8 DDD vs 0.2),  
carbamazepine (0.7 vs 0.2), oxcarbazepine (>1 vs 0.2), valproate (>1 vs 0.4), lamotrigine (>1 
vs 0.5), and topiramate (>1 vs 0.1). 
Psychiatric co-treatments were less common in EPI than in PSY: antipsychotics were used 
in 6% vs 67% (p<0.001), lithium in none vs 9% (p<0.001) and antidepressants in 7% vs 70% 
(p<0.001). 
The hierarchical classification system used prescriptions of antipsychotics, prescriptions of 
SSRIs and number of different AEDs to discriminate EPI and PSY with a probability greater 
than 0.93. Psychiatric co-therapies and therapy with ≥3FAE have the greatest discriminating 
power between EPI and PSI, as shown in Figure 2. 
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Figure 2 Hierarchical classification tree distinguishing  EPI and PSY 
 
 
 
The application of the algorithm to the 50 patients from Ferrara (44 with psychiatric disease, 
6  with epilepsy) allowed a correct diagnosis in 45 patients (90%).  
 
4.2 Linkage of IMER with other registries   
The linkage of IMER with CeDAP generated 2216 univocally linked records, as shown in 
Figure 3.  
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Figure 3- Flow chart of IMER-CEDAP linkage 
                                                   2297 IMER records 
  
                                                                                       36 non-RER inhabitants mothers  
           45 non-identifiable linkages   
                                                                                                     
                               2216 IMER records linked to CEDAP records 
                                      
                     
4.3 Identification of  pregnancies (deliveries and abortions) and drug exposure 
description 
The cohort of pregnancies, comprising the cohort of deliveries and that of abortions is 
represented in figure 4.  
  
Figure 4. Diagram of pregnancies, deliveries, abortions and newborns  
 
                                      145.243 pregnancies  
                                                                    
               111.284 deliveries                        33.959 abortions  
                                            
112.845 live births       279 stillbirths    16408 spontaneous    17551  induced 
             (1840 twin deliveries) 
 
 
Nine hundred and forty-one women were exposed to AEDs during the year preceding the 
delivery/abortion (0.65%): 815 were exposed to one AED, 108 to 2 AEDs, 16 to 3 AEDs, 2 to 
4 AEDs. The proportion of the single active substances is represented in figure 5.  
According to the algorithm, 561 of them (59,6%) had epilepsy.  
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Figure 5. AEDs exposure in the year preceding the delivery/abortion (n. of women) 
 
 
  
  
 
 
 
Six hundred and eleven women were exposed to AEDs during pregnancy  (0.42%, 95% CI: 
0.39-0.46%): 537 to one AED, 62 to two  AEDs, 10 to 3 AEDs, 2 to  4 AEDs.  The proportion 
of the single active substances is shown in Figure 6.  
 
 
 
Figure 6. Exposure to AEDs during pregnancy (number of women) 
 
 
  
 
 
 
 
 
 
 
 
 
Three hundred and fifty-three babies were exposed to AEDs during the first trimester of 
pregnancy (0.31%, 95% IC: 0.28-0.35%): 321 to one AED, 27 to two AEDs, 5  to three 
AEDs.  The proportion of the single active substances is shown in Figure 7.  According to the 
algorithm in 295 cases (83.6%) the maternal indication for AEDs was epilepsy.  
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Figure 7. Exposure to AEDs in the I trimester (number of newborns)  
 
 
 
 
 
The average daily doses of the active substances are shown in Table 1. No woman in our 
population was exposed to Rufinamide, Tiagabine, Felbamate or Lacosamide. 
 
 
 
Table 1 -  Average daily dose for single active substance in the first trimester or in the trimester preceding the abortion  
 
Active substance 
Mean St. dev Median 
1° 
quartile 
3° 
quartile N 
Phenobarbital 97.2 43.4 94.4 66.7 133.3 44 
Clonazepam 1.1 1.4 0.6 0.3 1.4 85 
Carbamazepine 540.6 370.2 444.4 266.7 800.0 120 
Oxcarbazepine 639.8 443.3 500.0 333.3 666.7 31 
Valproate 508.8 385.4 366.7 200.0 666.7 116 
Valpromide 800.0 565.7 800.0 400.0 1200 2 
Lamotrigine 214.1 222.3 124.5 62.2 248.9 99 
Topiramate 136.7 188.1 66.7 33.3 133.3 30 
Levetiracetam 1556 1026 1333 1000 2000 33 
Zonisamide 118.6 68.8 132.2 73.9 163.3 4 
 
 
 
 
 
 
4.4 Exposure to AEDs and risk of abortion 
 
Table 2 shows the outcome of the 145.243 pregnancies in the exposed and non-exposed 
women 
 
 
 
21 
 
Table 2-AEDs exposure and pregnancy outcome 
 
Pregnancy 
outcome Non-exposed Exposed 
 N  % N  % 
Delivery 110871 76,7 413 67,6 
 
Spontaneous 
abortion  16338 11,3 70 11,5 
Induced abortion 17423 12,0 128 20,9 
Total 144632 100 611 100 
 
 
 
 
 
 
Table 3 and 4 show the risk of induced abortion (TOP: termination of pregnancy) and 
exposure to AEDs in the year preceding the event and in the trimester preceding the event 
(pregnancy). The risk of induced abortion was significantly increased after exposure to  
AEDs, with a positive relation to the number of taken AEDs. 
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Active 
substance Exposed N TOPs % OR 95% CI 
All No 128045 17319 13.5 1 . . 
 Yes 790 232 29.4 2.658 2.279 3.101 
PB No 128778 17541 13.6 1 . . 
 Yes 57 10 17.5 1.350 0.682 2.671 
PRI No 128832 17550 13.6 1 . . 
 Yes 3 1 33.3 NA NA NA 
PHT No 128829 17546 13.6 1 . . 
 Yes 6 5 83.3 NA NA NA 
ETS No 128831 17551 13.6 1 . . 
 Yes 4 0 0 NA NA NA 
CNZ No 128686 17497 13.6 1 . . 
 Yes 149 54 36.2 3.612 2.586 5.047 
CBZ No 128675 17507 13.6 1 . . 
 Yes 160 44 27.5 2.409 1.702 3.409 
OXC No 128797 17535 13.6 1 . . 
 Yes 38 16 42.1 4.616 2.424 8.790 
VPA No 128678 17504 13.6 1 . . 
 Yes 157 47 29.9 2.714 1.928 3.820 
Valpromide No 128832 17551 13.6 1 . . 
 Yes 3 0 0 NA NA NA 
VGB No 128834 17551 13.6 1 . . 
 Yes 1 0 0 NA NA NA 
LTG No 128722 17529 13.6 1 . . 
 Yes 113 22 19.5 1.536 0.964 2.447 
TPM No 128765 17525 13.6 1 . . 
 Yes 70 26 37.1 3.751 2.309 6.093 
GBP No 128796 17538 13.6 1 . . 
 Yes 39 13 33.3 3.172 1.630 6.174 
     LEV No 128795 17541 13.6 1 . . 
 Yes 40 10 25 2.114 1.033 4.326 
ZNS No 128833 17551 13.6 1 . . 
 Yes 2 0 0 NA NA NA 
PGB No 128770 17524 13.6 1 . . 
 Yes 65 27 41.5 4.511 2.754 7.390 
 
 
                           Table 3. Risk of induced abortion and exposure to AEDS in the year preceding the event   
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                           Table 4. Risk of induced abortion and exposure to AEDS in the trimester preceding the event   
 
Active 
substance Exposed N TOPs % OR 95% CI 
All No 128294 17423 13.6 1 . . 
 Yes 541 128 23.7 1.972 1.616 2.406 
PB No 128788 17544 13.6 1 . . 
 Yes 47 7 14.9 1.114 0.500 2.485 
PRI No 128832 17550 13.6 1 . . 
 Yes 3 1 33.3 NA NA NA 
PHT No 128833 17549 13.6 1 . . 
 Yes 2 2 100 N.D N.D N.D 
ETS No 128831 17551 13.6 1 . . 
 Yes 4 0 0 NA NA NA 
CNZ No 128742 17524 13.6 1 . . 
 Yes 93 27 29 2.597 1.659 4.064 
CBZ No 128706 17524 13.6 1 . . 
 Yes 129 27 20.9 1.684 1.102 2.574 
OXC No 128806 17539 13.6 1 . . 
 Yes 29 12 41.4 4.479 2.139 9.379 
VPA No 128728 17521 13.6 1 . . 
 Yes 107 30 28 2.473 1.621 3.772 
Valpromide No 128833 17551 13.6 1 . . 
 Yes 2 0 0 NA NA NA 
LTG No 128744 17536 13.6 1 . . 
 Yes 91 15 16.5 1.252 0.719 2.178 
TPM No 128808 17545 13.6 1 . . 
 Yes 27 6 22.2 1.821 0.736 4.506 
GBP No 128815 17543 13.6 1 . . 
 Yes 20 8 40 4.229 1.728 10.346 
     LEV No 128801 17543 13.6 1 . . 
 Yes 34 8 23.5 1.965 0.891 4.335 
ZNS No 128833 17551 13.6 1 . . 
 Yes 2 0 0 NA NA NA 
PGB No 128811 17544 13.6 1 . . 
 Yes 24 7 29.2 2.612 1.083 6.299 
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 Table 5. Risk of induced abortion per number of AEDs   
 
Exposure period 
Number of 
AEDs N TOPs % OR 95% CI 
Previous 12 
months 
0 128045 17319 13.5 1 . . 
 1 687 196 28.5 2.552 2.161 3.014 
 >=2 103 36 35 3.435 2.291 5.152 
Pregnancy 0 128294 17423 13.6 1 . . 
 1 479 110 23 1.897 1.532 2.349 
 >=2 62 18 29 2.603 1.504 4.506 
 
 
4.5 Exposure to AEDs during the first trimester and risk of MCMs 
 
During the three-year period of observation 2302 cases of newborns with MCMs were 
reported to the IMER. Nine were exposed to AEDs in utero, of whom 8 during the first 
trimester. According to the algorithm 6 of the mothers had epilepsy.  
The incidence of MCMs was 2.3% in the newborns from exposed mothers (first trimester) 
and 2.0% in the newborns from non-exposed mothers. According to the clinical indication 
drawn by the algorithm, the incidence of MCMs in babies born to WWE exposed to AEDs 
was 2.0%.   
The risk of MCMs increased when the mother was exposed to more than one AED, as 
reported in table 6. 
The risk of MCMs for each single AED is reported in Table 7, while Table 8 reports the risk of 
MCMs for each AED in monotherapy or polytherapy. 
The specific MCMs reported in the exposed group are listed in Table 9.  The only anomaly 
which occurred in more than one baby was the ventricular septal defect (VSD). This MCM 
had a prevalence of 84.98 per 10000 liveborns in the exposed population versus 33.81 per 
10000 liveborns in the not exposed. Table 9 reports also the supposed diagnosis according 
to the algorithm.  
   
Table 6- AEDs number and MCMs 
    Unadjusted Adjusted* 
N of AEDs N MCMs % OR 95% CI OR 95% CI 
0 112771 2294 2 1 . . 1 . . 
1 321 7 2.2 1.074 0.507 2.273 1.002 0.473 2.124 
>=2 32 1 3.1 1.562 0.214 11.389 1.440 0.196 10.588 
    OR adjusted for maternal age, education, smoking habit, diabetes and prescription of drugs belonging to X and D FDA pregnancy 
    categories and foetal confounding pathologies of different etiologies  
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Table 7-  Single AEDs and risk of MCMs 
     Unadjusted Adjusted* 
Active 
substance Exposed N MCM % OR 95% CI OR 95% CI 
All No 112771 2294 2 1 . . 1 . . 
 Yes 353 8 2.3 1.117 0.553 2.254 1.042 0.515 2.104 
PB No 113092 2301 2 1 . . 1 . . 
 Yes 32 1 3.1 1.561 0.214 11.386 1.538 0.209 11.305 
PRI No 113123 2302 2 1 . . 1 . . 
 Yes 1 0 0 N.D N.D N.D N.D N.D N.D 
ETS No 113120 2301 2 1 . . 1 . . 
 Yes 4 1 25 N.D N.D N.D N.D N.D N.D 
CNZ No 113075 2301 2 1 . . 1 . . 
 Yes 49 1 2 1.000 0.138 7.268 0.873 0.120 6.338 
CBZ No 113043 2300 2 1 . . 1 . . 
 Yes 81 2 2.5 1.219 0.300 4.963 1.178 0.289 4.798 
OXC No 113108 2302 2 1 . . 1 . . 
 Yes 16 0 0 N.D N.D N.D N.D N.D N.D 
VPA No 113055 2302 2 1 . . 1 . . 
 Yes 69 0 0 N.D N.D N.D N.D N.D N.D 
Valpromide No 113122 2302 2 1 . . 1 . . 
 Yes 2 0 0 N.D N.D N.D N.D N.D N.D 
LTG No 113056 2301 2 1 . . 1 . . 
 Yes 68 1 1.5 0.719 0.100 5.177 0.682 0.095 4.921 
TPM No 113105 2302 2 1 . . 1 . . 
 Yes 19 0 0 N.D N.D N.D N.D N.D N.D 
GBP No 113114 2300 2 1 . . 1 . . 
 Yes 10 2 20 12.109 2.576 56.914 9.863 2.081 46.753 
LEV No 113101 2302 2 1 . . 1 . . 
 Yes 23 0 0 N.D N.D N.D N.D N.D N.D 
ZNS No 113122 2302 2 1 . . 1 . . 
 Yes 2 0 0 N.D N.D N.D N.D N.D N.D 
PGB No 113110 2301 2 1 . . 1 . . 
 Yes 14 1 7.1 3.717 0.488 28.342 2.989 0.390 22.920 
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Table 8- Single AEDs and risk of MCMs in monotherapy/polytherapy  
Active 
substance  Exposure N MCMs % OR 95% CI 
PB No 113092 2301 2 - - - 
 Monotherapy 23 0 0 - - - 
 Politherapy 9 1 11.1 - - - 
PRI No 113123 2302 2 - - - 
 Monotherapy 1 0 0 - - - 
 Polytherapy . . . - - - 
ETS No 113120 2301 2 - - - 
 Monotherapy . . . - - - 
 Polytherapy 4 1 25 - - - 
CNZ No 113075 2301 2 1 - - 
 Monotherapy 44 1 2.3 1.120 0.154 8.134 
 Polytherapy 5 0 0 N.D N.D N.D 
CBZ No 113043 2300 2 1 . . 
 Monotherapy 71 2 2.8 1.396 0.342 5.696 
 Polytherapy 10 0 0 N.D N.D N.D 
OXC No 113108 2302 2 - - - 
 Monotherapy 14 0 0 - - - 
 Polytherapy 2 0 0 - - - 
VPA No 113055 2302 2 - - - 
 Monotherapy 59 0 0 - - - 
 Polytherapy 10 0 0 - - - 
Valpromide No 113122 2302 2 - - - 
 Monotherapy 1 0 0 - - - 
 Polytherapy 1 0 0 - - - 
LTG No 113056 2301 2 1 . . 
 Monotherapy 59 1 1.7 0.830 0.115 5.994 
 Polytherapy 9 0 0 N.D N.D N.D 
TPM No 113105 2302 2 - - - 
 Monotherapy 15 0 0 - - - 
 Polytherapy 4 0 0 - - - 
GBP No 113114 2300 2 - - - 
 Monotherapy 6 2 33.3 24.090 4.410 131.588 
 Polytherapy 4 0 0 N.D N.D N.D 
LEV No 113101 2302 2 - - - 
 Monotherapy 14 0 0 - - - 
 Polytherapy 9 0 0 - - - 
ZNG No 113122 2302 2 - - - 
 Monotherapy 2 0 0 - - - 
 Polytherapy . . . - - - 
PGB No 113110 2301 2 1 . . 
 Monotherapy 12 1 8.3 4.378 0.565 33.923 
 Polytherapy 2 0 0 N.D N.D N.D 
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Table 9- Types of MCMs in children from exposed mothers 
Type of MCM 
 
Number of affected babies AEDs  Supposed diagnosis 
Ventricular septal defect(VSD)
  
3 GBP; GBP; PGB Epi; Epi; Psy 
Atrial septal defect, tricuspid 
insufficiency 
1 LTG Epi 
Bilateral Postaxial polydactyly 1 CBZ Epi 
Ectopic Kidney   1 CNZ Psy 
Congenital diaphragmatic 
hernia  
1 CBZ Epi 
Multiple congenital Anomalies  
+ Hypospadias  
1 PB+ETS 
 
Epi 
 
4.6 Exposure to AEDs and risk of stillbirth  
During the period of observation there were 278 stillbirths in the non-exposed group, with an 
incidence of 25 per 10.000  and 1 in the exposed group, with an incidence of 28 per 10.000   
 
4.7 Exposure to AEDs and risk of fetal growth retardation (FGR) 
Table 10 reports  the risk of FGR per number of AEDs and table 11 and 12 report the risk of 
FGR for single AEDs use in pregnancy and in the first trimester. There is a slightly higher 
risk for FGR after exposure to AEDs in the first trimester, increasing with polytherapy.     
 
Table 10- Risk of foetal growth retardation per number of AEDs 
Exposure 
period 
Number 
of AEDs N FGR % OR 95% CI 
Previous 12 
months 
0 112562 11201 10 1 . . 
 1 495 57 11.5 1.177 0.893 1.553 
 >=2 67 10 14.9 1.592 0.813 3.116 
Pregnancy 0 
 
112708 11215 10 1 . . 
 1 372 48 12.9 1.341 0.990 1.817 
 >=2 44 5 11.4 1.160 0.457 2.944 
First 
trimester 
0 112771 11220 9.9 1 . . 
 1 321 43 13.4 1.401 1.015 1.932 
 >=2 32 5 15.6 1.683 0.649 4.365 
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Table 11- Fetal growth retardation and AEDs use during pregnancy  
Active 
substance Exposure N FGR % OR 95% CI 
All No 112708 11215 10 1 . . 
 Yes 416 53 12.7 1.322 0.990 1.764 
PB No 113084 11263 10 1 . . 
 Yes 40 5 12.5 1.292 0.506 3.297 
PRI No 113122 11268 10 1 . . 
 Yes 2 0 0 N.D N.D N.D 
PHT No 113124 11268 10 1 . . 
ETS No 113120 11268 10 1 . . 
 Yes 4 0 0 N.D N.D N.D 
CNZ No 113057 11257 10 1 . . 
 Yes 67 11 16.4 1.776 0.930 3.391 
CBZ No 113021 11260 10 1 . . 
 Yes 103 8 7.8 0.761 0.370 1.566 
OXC No 113107 11267 10 1 . . 
 Yes 17 1 5.9 0.568 0.076 4.262 
VPA No 113046 11257 10 1 . . 
 Yes 78 11 14.1 1.487 0.786 2.812 
Valpromide No 113122 11267 10 1 . . 
 Yes 2 1 50 N.D N.D N.D 
VGB No 113124 11268 10 1 . . 
LTG No 113048 11259 10 1 . . 
 Yes 76 9 11.8 1.214 0.605 2.436 
TPM No 113103 11266 10 1 . . 
 Yes 21 2 9.5 0.952 0.222 4.086 
FBM No 113112 11263 10 1 . . 
 Yes 12 5 41.7 6.460 2.050 20.356 
LEV No 113098 11265 10 1 . . 
 Yes 26 3 11.5 1.192 0.360 3.951 
ZNS No 113122 11267 10 1 . . 
 Yes 2 1 50 N.D N.D N.D 
PGB No 113107 11265 10 1 . . 
 Yes 17 3 17.6 1.959 0.565 6.786 
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Table 12- Fetal growth retardation and AEDs use during the first trimester 
Active 
substance Exposure N FGR % OR 95% CI 
All No 112771 11220 9.9 1 . . 
 Yes 353 48 13.6 1.426 1.051 1.934 
PB No 113092 11263 10 1 . . 
 Sì 32 5 15.6 1.681 0.648 4.360 
PRI No 113123 11268 10 1 . . 
 Sì 1 0 0 N.D N.D N.D 
PHT No 113124 11268 10 1 . . 
ETS No 113120 11268 10 1 . . 
 Sì 4 0 0 N.D N.D N.D 
CNZ No 113075 11260 10 1 . . 
 Sì 49 8 16.3 1.775 0.833 3.781 
CBZ No 113043 11262 10 1 . . 
 Sì 81 6 7.4 0.723 0.315 1.661 
OXC No 113108 11267 10 1 . . 
 Sì 16 1 6.3 0.605 0.080 4.563 
VPA No 113055 11257 10 1 . . 
 Sì 69 11 15.9 1.724 0.906 3.281 
Valpromide No 113122 11267 10 1 . . 
 Sì 2 1 50 N.D N.D N.D 
VGB No 113124 11268 10 1 . . 
LTG No 113056 11259 10 1 . . 
 Sì 68 9 13.2 1.380 0.684 2.783 
TPM No 113105 11266 10 1 . . 
 Sì 19 2 10.5 1.065 0.246 4.606 
GBP No 113114 11264 10 1 . . 
 Sì 10 4 40 6.027 1.701 21.361 
LEV No 113101 11265 10 1 . . 
 Sì 23 3 13 1.356 0.403 4.564 
ZNS No 113122 11267 10 1 . . 
 Sì 2 1 50 N.D N.D N.D 
PGB No 113110 11265 10 1 . . 
 Sì 14 3 21.4 2.466 0.688 8.839 
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5. DISCUSSION 
 
A first achievement of our study was the design of an algorithm which proved to be very 
accurate in discriminating women who are AEDs users for epilepsy from women who use 
them for a  psychiatric disorder, on the basis of their prescriptions.  The application of the 
algorithm to external data resulted in a good predictive ability of the diagnosis based on the 
prescription pattern showing, by comparison with the actual diagnosis, an error rate of 10% 
(5 subjects out of 50), dramatically close to the cross validation estimate. An obvious 
limitation of this approach is that it cannot be applied to other clinical indications. Women 
who use AEDs for other disorders, such as migraine, would probably be misclassified as 
epileptic, as they generally do not have psychiatric co-prescriptions. For our purpose, we 
hypothesized that the algorithm could prove useful, as, in pregnant women, indications 
different from epilepsy and psychiatric disorders are supposed to be very rare.  
The prevalence of AEDs use in the first trimester of pregnancy in our population, 4 per 1000 
pregnancies, or 3.1 per 1000 deliveries, is comparable to the data reported by other Authors 
(Czeizel et al., 1992; Malm et al., 2003; Wide et al., 2004; Kilic et al., 2014; Wen et al., 
2015). Our results could be slightly underestimated, as clobazam, a benzodiazepine not 
rarely used in epilepsy, is not reimbursable and therefore not traceable. However, this drug 
is only very rarely used as a monotherapy, so it is unlikely that a significant proportion of 
exposed women were misclassified as unexposed.  
Unlike recent reports from Denmark and the USA (Kilic et al., 2014; Wen et al., 2015), 
according to which lamotrigine was the most used drug in pregnancy, carbamazepine was 
the most used AED in RER, being taken in 23% of all the exposed pregnancies. 
Levetiracetam was  much less used in our population  (5.9% of the total used AEDs) than it 
was described in the more recent literature (Meador et al., 2009; Moolgard-Nielsen and 
Hviid, 2011; Kilic et al., 2014; Wen et al., 2015). It is likely that prescribing patterns vary in 
different regions.  A striking finding of our study is that approximately one in five AEDs users 
was taking valproate, which is currently known as the most dangerous AED in pregnancy, 
due to its higher teratogenic risk, but also to possible cognitive and developmental 
detrimental effects as demonstrated by recent studies (Velez-Ruiz NJ and Meador KJ, 2015).  
One possible explanation of the unexpected over-representation of valproate is that this drug 
is used both in epilepsy and in psychiatric disorders; indeed one study investigating trends of 
use of AEDs in pregnant women showed that over time valproate use decreased overall, but 
not in patients with a psychiatric disorder (Wen et al., 2015). It is worth considering also that 
valproate is still one of the most effective drugs in some type of seizures and epileptic 
syndromes, and in particular generalized idiopathic epilepsies, which are common in the 
young (Marson et al., 2006) and it showed to be more effective in maintaining seizure 
freedom in pregnancy than less teratogenic drugs (EURAP Study Group, 2006; Hernandez-
Diaz et al., 2012). Lastly, taking into account the limitations of the ascertainment methods, 
the mean dose of VPA in our population should be considered a low dose, associated with a 
lower risk (Tomson et al., 2011; Hernandez-Diaz et al., 2012; Campbell et al., 2014).  
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However, an auditing with the neurologists and psychiatrists of the Region could be 
beneficial for verifying and raising their awareness of the warnings on the use of valproate in 
women of childbearing age.      
One very interesting finding of our study was the almost two-fold risk of induced abortion in 
women taking AEDs; furthermore there is a clear trend towards an increased risk when more 
than one AED is used. There is one first important limitation in case ascertainment of 
abortions: due to the Italian privacy policy, the ICD codes related to induced terminations of 
pregnancy are no longer reported in the Hospital discharge registry (SDO) with the unique 
anonymous code which allows to link these data to the other registers. However, since 
adjustments to the law have been carried out at different times, data from some hospitals 
were available for a longer period, including our period of observation. Overall, considering 
the regional anonymous statistical data (ISTAT) for the previous years (the ones concerning 
the period 2009-11 are not available yet) we estimated that approximately one half of the 
induced abortions were lost. We believe that this did not significantly affect our results. In 
fact there is no reason to hypothesize that in some hospitals women taking AEDs were more 
represented among women who underwent an abortion, than in others. A possible 
explanation for our results on abortions could be an excess of malformations in the exposed 
foetuses , detected by prenatal ultrasound. This would be relevant, indicating that studies on 
malformations detected only on deliveries are only partially reliable. On the other hand, 
physicians taking care of women with epilepsy well know from their everyday practice  that a 
significant number of them, faced with an unplanned pregnancy, choose very early to 
terminate their pregnancy, due to a groundless fear of the pregnancy outcome. These 
“unnecessary” abortions are the result of a malpractice which would deserve, as well, to be 
clearly delineated and effectively tackled.  Unfortunately, again due to the Italian privacy 
policy, it was impossible to have further information on the abortions, including the 
gestational age, which could have allowed the distinction between abortion in the first 
trimester, in which a malformation could very rarely have been identified, and abortions in 
the second trimester, in which a severe pathology of the foetus or, much more rarely, of the 
mother, must have been present. Further studies are needed to understand the excess of 
terminations of pregnancy in this population.  
In agreement with the literature data, the rate of spontaneous abortions was almost 
superimposable in the exposed and non-exposed women and so was the risk of stillbirth. 
The malformation rate in the exposed population exceeded only slightly the one of the non-
exposed, indeed, after adjusting for confounding factors the OR was very close to 1 (1.042). 
However the risk increased on polytherapy, showing an evident trend to a higher risk after 
exposure to AEDs.  
Caution is needed in speculating on single AEDs or specific malformations, due to the little 
number of MCMs. However we found a significant higher risk of ventricular septal defect, 
which had a more than twofold higher prevalence in the exposed population. Interestingly, in 
two of the three cases, there was a maternal exposure to gabapentin and in the third to 
pregabalin, a molecule which has a similar chemical and pharmacodynamic profile.  In the 
literature there are still a few data on teratogenicity of gabapentin, which seem to point 
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toward a low risk. However, the only malformation reported over 11 exposures was 
ventricular septal defect in the study by Morrow et al. (2006) and the only malformation 
reported over 59 exposures was a not further specified “congenital heart disease” in the 
study by Molgaard-Nielsen and Hviid (2011).  Further larger studies are needed to 
investigate a possible association between intrauterine exposure to gabapentin and 
pregabalin and ventricular septal defect.   
According to our algorithm, 6 out of 8 women who gave birth to a child with a congenital 
anomaly, had epilepsy. This result would lead to an incidence of MCMs in babies born to 
WWE exposed to AEDs of 2.0%, equal to the one of the non-exposed population. However 
two of them were on monotherapy with gabapentin. As this drug is commonly used in 
monotherapy for neuropathic pain, and this diagnosis would not be ruled out by our 
algorithm, we believe more caution than previously thought must be used to interpret the 
result. Further refinements of the algorithm, allowing the inclusion of women with indications 
other from epilepsy and psychiatric disorders might be needed, as these indications might be 
more frequent in pregnancy than expected (Guttuso et al., 2014).          
In agreement with some studies, we found that being exposed to AEDs in utero, and 
especially in the first trimester, carried a slightly higher risk of fetal growth retardation. The 
risk was higher in polytherapy.  
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CONCLUSIONS 
The prevalence of AED use in pregnancy in Emilia Romagna Region is similar to the one 
found in other regions and countries, concerning approximately 4 out of 1000 pregnancies. 
Valproate might be over-used in pregnancy in Emilia Romagna. An audit with neurologists 
and psychiatrists could be beneficial for raising awareness on the appropriateness of 
switching to another, less teratogenic drug, whenever possible.    
Our data indicate that major congenital malformations and other foetal adverse outcomes do 
show a slightly higher prevalence after intrauterine exposure to AEDs, especially in 
polytherapy, but they are still infrequent. For this reason pregnancy should not routinely be 
designated at high risk in patients taking these drugs. 
Further studies are needed to investigate a possible association between intrauterine 
exposure to gabapentin and pregabalin and ventricular septal defect.  
To our knowledge, this is the first study investigating the prevalence of induced termination 
of pregnancy in women taking AEDs. Even taking into account the limitations of case 
ascertainment, the high prevalence of induced abortions in our population raises concerns 
and deserves further studies to clarify its causes.   
This work allowed the creation of a network among neurologists, gynaecologists, 
neonatologists and pharmacologists and led to the design of a dedicated database that links 
data on AEDs prescriptions, deliveries, congenital anomalies and other foetal outcomes. 
Therefore  it may constitute the premises for a permanent surveillance system of pregnancy 
outcomes in women taking AEDs in the Emilia Romagna Region.  
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APPENDIX 1 
 
Abbreviations used in the text 
  
AED Antiepileptic Drugs 
GTCS Generalized tonic-clonic seizures 
MCM Major Congenital Malformation 
PB Phenobarbital 
PHT Phenytoin 
VPA Valproate 
CBZ Carbamazepine 
LTG Lamotrigine 
LEV Levetiracetam 
TPM Topiramate 
WWE Women With Epilepsy 
RER 
 
Regione Emilia Romagna 
ATC Anatomical Therapeutic Chemical 
(classification system) 
FGR Foetal Growth Retardation 
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APPENDIX 2 
 
 AEDs indications other than epilepsy (including off-label indications) 
Clonazepam (CNZ) Anxiety, insomnia, restless legs syndrome, 
tremor, myoclonus 
Carbamazepine (CBZ) and oxcarbazepine 
(OXC) 
trigeminal neuralgia, bipolar syndrome, 
neuropathic pain, myotonia, cramps, 
alcohol withdrawal syndrome 
Gabapentin (GBP), Pregabalin (PGB)  Neuropathic pain, trigeminal neuralgia, 
tremor, fibromyalgia 
Lamotrigine (LTG) migraine prophylaxis, SUNCT syndrome, 
neuropathic pain, fibromyalgia 
Phenobarbital (PB) and primidone (PRI) 
 
Anxiety, other barbiturates withdrawal 
syndrome, essential tremor 
Topiramate (TPM) migraine prophylaxis, alcoholism, obesity 
Valproic acid (VPA)   migraine prophylaxis, bipolar syndrome 
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